The spectrum of use of rituximab in chronic lymphocytic leukemia

Alessandra Tedeschi
Eleonora Vismara
Francesca Ricci
Enrica Morra
Marco Montillo
Department of Hematology, Niguarda Ca’ Granda Hospital, Milano, Italy

Abstract: The monoclonal chimeric anti-CD20 antibody, rituximab, has considerably improved therapeutic outcome in B-cell chronic lymphocytic leukemia. Rituximab has limited clinical activity when used as a single agent. The combination of the monoclonal antibody with fludarabine-based regimens clearly demonstrated, in Phase II and randomized trials, an increase in clinical efficacy in previously untreated and pretreated patients. Furthermore the addition of rituximab enabled the eradication of minimal residual disease, which is correlated with the prognosis in a high proportion of patients. Although the combination of rituximab with fludarabine-based regimens increased myelosuppression and immunosuppression, incidence of infections did not increase. The benefit of adding rituximab to other purine analogs or other chemotherapeutic combination regimens has also been explored. Moreover there could be a role for achieving better quality of responses with the combination of different monoclonal antibodies, considering that they target different antigens and exert different mechanism of action. Although the role of rituximab as maintenance therapy in low grade non-Hodgkin’s lymphomas has been determined, the benefit and optimal schedule in chronic lymphocytic leukemia are still under investigation. This review brings together knowledge of the pharmacokinetics, mechanism of action and clinical use of rituximab in chronic lymphocytic leukemia.

Keywords: rituximab, B-cell chronic lymphocytic leukemia, first-line treatment, refractory/relapsed

Introduction

B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, with an annual incidence of 3 to 5 cases per 100,000.1 The disease is rare in people younger than 50 years, but incidence rises fairly rapidly above this age. The median age at diagnosis, according to Surveillance, Epidemiology and End Results (SEER), is 70 years for men and 74 years for women.1

Overall survival (OS) rate in CLL after diagnosis ranges from less than 2 to more than 15 years, with a median of 9 years, because the clinical course is extremely variable. A third of patients never need treatment and have long survival, in another third an initial indolent phase is followed by disease progression, and the remaining third exhibit aggressive disease at onset and need immediate treatment.2

Although clinical stagings proposed in the early 1980s by Binet et al3 and Rai et al4 are still widely used as prognostic factors in CLL, these systems do not enable identification of patients in early stages who are likely to progress and those in whom the disease will remain stable for many years.

In recent years, several biological markers – mutation status of the immunoglobulin heavy chain variable chain (IgVH), expression of ZAP-70, expression of CD38,
chromosome abnormalities identified by fluorescence in situ hybridization (FISH) analysis, and P53 mutations—have been identified as important prognostic factors. These factors, as well as other historical serological parameters such as beta2-microglobulin,11 proved to be useful in predicting which patients would develop progressive disease. Furthermore, they may provide prognosis assessment for response to treatment, response duration, and survival.

In routine clinical practice, therapy should not be initiated in patients who have asymptomatic CLL, including those with Rai stage 0 or Binet stage A, until disease progression or unless disease-related symptoms are evident. The observation that early treatment in asymptomatic patients does not prolong survival is supported by a meta-analysis.12 In seven trials including 2048 early-stage patients randomly allocated to immediate or deferred treatment with chlorambucil (with or without prednisolone) no benefit for either treatment group was observed.

However, the potential benefit of an early intervention therapy according to prognostic factors and novel agents, including monoclonal antibodies, requires further study. Current trials are ongoing in Europe and in the United States (US) to re-address this issue using more efficient treatments and considering patients with high-risk features.

Widely accepted guidelines for the initiation of chemotherapy in CLL have been proposed by the National Cancer Institute Sponsored Working Group13 and have been recently reviewed by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL).14 According to these guidelines, the criteria for initiation of therapy may not be identical for routine clinical practice and for clinical trials.

Despite improvement in therapy, CLL remains incurable with standard therapy. Patients inevitably relapse, becoming increasingly refractory to treatment and often acquiring high-risk chromosomal abnormalities. In the past two decades the introduction of purine analogs, most notably fludarabine, has had an important effect on CLL management.15 Fludarabine has demonstrated greater efficacy than chlorambucil or CAP (cyclophosphamide, doxorubicin and prednisone) in obtaining higher response rates, complete remission (CR) rates and progression-free survival (PFS).16–18 The advantages were greater when purine nucleoside analogs were combined with cyclophosphamide and/or mitoxantrone.19–21

However, studies with purine analogs–based chemotherapy failed to show an advantage in terms of OS.22 The same observation can be applied when considering results obtained with other chemotherapeutic agents administered alone or in combination treatments.

A recent advance in the treatment of CLL is the development of monoclonal antibodies directed against specific proteins expressed by CLL B-cells. Both alemtuzumab and rituximab, the two antibodies with the most clinical value in CLL, were shown to be active when used in monotherapy.23–24 The preclinical evidence of the synergistic effect between monoclonal antibodies and chemotherapeutic agents25,26 and the need for new association treatments, based on drugs with different mechanisms of actions possibly without adding major toxicities, prompted the investigation of immunochemotherapeutic regimens. Treatment strategies including monoclonal antibodies not only improved response rates, but also achieved better quality of responses, with minimal residual disease (MRD) being eradicated in a significant proportion of patients.27–29

The achievement of MRD, as determined by flow-cytometry or polymerase chain reaction (PCR)-based amplification of the IgVH rearrangement, is correlated with an improvement in time to retreatment and PFS. In 2005, Moreton et al first correlated the eradication of MRD with an improvement of OS after alemtuzumab monotherapy treatment in relapsed CLL patients.30 However, even if immunochemotherapy has eradicated MRD, patients will eventually relapse, as published trials have failed to demonstrate a plateau of PFS and OS curves. Although eradication of MRD may improve prognosis, prospective clinical trials are needed to define whether additional treatment administered to eradicate MRD provides significant benefit to clinical outcome.

To address this issue, MRD negativity has been adopted as a recommended trial endpoint in the recently updated diagnostic and treatment guidelines of the IWCLL working group.14 Allogeneic stem cell transplantation offers the possibility of a definite cure, but despite recent developments, such as reduced intensity conditioning and better supportive care, it is still associated with significant morbidity and mortality. However, in patients carrying del17p, requiring treatment, an allogeneic transplant should be considered as a therapeutic option that may induce long-lasting remissions.33

The current review brings together knowledge of the pharmacokinetics, mechanisms of action, and clinical use of rituximab in CLL.

**Mechanism of action, pharmacokinetics of rituximab**

Rituximab is a chimeric human/mouse Ig1-kappa antibody that targets the CD20 antigen. The chimeric structure of rituximab incorporates murine variable regions and human
constant kappa and Fc regions to diminish the development of anti-mouse immunoglobulin antibody side effects and possibly resistance.44

CD20, a cell-surface glycoprotein, is a calcium channel that interacts with the B-cell immunoglobulin receptor complex. CD20 is tightly restricted to the B-cell lineage and is expressed on the cell surface of more than 95% of normal and malignant B-cells, excluding stem cells and plasma cells.35 However, there are several differences in CD20 expression between B-cell malignancies. In contrast to B-cell lymphomas, which uniformly express CD20 strongly, relatively low levels of CD20 are typically expressed in CLL.36

Rituximab exerts its anticancer effects through more than one mechanism of action. The predominant mechanisms of rituximab-induced cell death are proposed to be the result of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis.37–41

The relative importance of these mechanisms may differ between CLL and B-cell non-Hodgkin’s lymphomas (NHL).

ADCC seems to be the predominant mechanism for the clearance of neoplastic cells in lymphomas, and Fc-γ receptors are critical for the in vivo actions of rituximab. The difference in response rates among lymphoma patients according to Fc-γ RIIIA polymorphisms supports the importance of ADCC in the in vivo actions of rituximab.42 In contrast, in CLL, Fc-γ RIIIA polymorphisms are not predictive for response.43 In vitro studies with rituximab have shown CDC to be more rapid and effective at inducing cell death than ADCC or apoptosis,40,44 particularly for blood-borne diseases, such as the leukemic-phase of B-cell NHL, including CLL, in which access to complement may be enhanced. Complement activation may be important, as increased expression of complement inhibitors CD55 and CD59 resulted in resistance to rituximab in B-NHL cell lines and CLL cells.44,45 However, caspase-3 activation and induction of apoptosis, using a pathway similar to that of fludarabine and other chemotherapeutic agents, appear to play a more important role in CLL than in B-cell NHL.44,46,47

In addition to the efficacy of rituximab in inducing a proapoptotic signal via the cell surface target structure, several studies have pointed out the activity of rituximab in promoting cellular responses against tumors. Selenko et al. demonstrated in vitro that the monoclonal anti-CD20 antibody promotes uptake and cross-presentation of lymphoma cell-derived peptides by antigen-presenting dendritic cells inducing maturation of dendritic cells, and allows the generation of specific cytotoxic T-cells that may have a long-lasting protective effect.45,49 Although this mechanism remains to be proved in vivo, the evidence of tardive and prolonged responses to rituximab treatment suggests that there is the potential for long-lasting antitumor protection.

**Rituximab as a single agent**

Single-dose Phase I trials showed the antibody to be well tolerated, with a half-life of 4 days.50 Multiple-dose schedules were developed and the Phase II trials explored a four-dose schedule.51,52 In the US Phase II trial 166 patients with relapsed low-grade lymphomas received rituximab at a dose of 375 mg/m² weekly for four consecutive weeks.52 The subgroup of 33 patients with small lymphocytic lymphoma (SLL), the tissue counterpart of CLL, achieved a significantly lower response rate than those with follicular lymphoma (12% vs 58%; P < 0.01). Subsequent studies in relapsed CLL with rituximab administered at a dose of 375 mg/m² weekly for 4 weeks also showed a lower response rate than usually seen in NHL, with almost all responses being categorized as partial remissions (Table 1).53–60

Two studies explored the efficacy of rituximab in first-line treatment.59,60 Hainsworth et al. achieved an initial overall response rate (ORR) of 51% (4% CR) after initial standard rituximab regimen, increasing to 70% after maintenance therapy in CLL/SLL patients.59 A high ORR (90%, 9% CR), was also reported by Thomas et al in 21 CLL patients with Rai stage 0, I, II disease and elevated beta2-microglobulin level without other indications of therapy.50 Although rituximab used in first-line treatment was shown to be more effective than in the setting of relapsed/refractory patients, the drug in CLL/SLL is still less active than in follicular lymphomas. Furthermore, better quality of responses and more prolonged PFS can be obtained with fludarabine in monotherapy, albeit with more substantial toxicity.61

Several explanations have been considered for the reduced responsiveness of CLL/SLL to monoclonal antibody treatment. CD20 expression in CLL/SLL is significantly lower than in other types of NHL, which may affect the degree of antibody binding.37 However Perz et al. could not identify a correlation between CD20 expression and efficacy of rituximab treatment.36 Another mechanism could be the rapid clearance of the antibody from the circulation due to the high number of circulating cells in CLL, which may give a lower serum concentration. Furthermore, because high levels of soluble CD20 have been demonstrated in plasma of patients with CLL,63 it is theoretically possible that circulating CD20 may deplete the concentration of rituximab available for binding to the tumor cells.
Whatervhether the reason for the poorer responses, pharma-
cokinetic studies conducted in relapsed refractory NHL
showed markedly lower levels of circulating rituximab in
the serum of patients with Working Formulation A disease.52

The standard regimen of 375 mg/m² weekly for 4 weeks
was established for the treatment of NHL on the basis of effi-
cacy and maximum tolerated dose in a dose escalation study; however patients receiving higher dosages of the monoclonal
antibody showed no evidence of dose-limiting toxicity.64
This was the rationale for increasing dosing of rituximab
in CLL in order to maintain high antibody concentrations
in serum and possibly overcome its rapid clearance by the
large number of circulating CLL cells.

Both dose-intensive and dose-intensity strategies have been
considered in previously treated patients.

O’Brien et al designed a dose escalation study with an
initial infusion of 375 mg/m² followed by three further esca-
lating doses ranging from 500 mg to 2250 mg/m².57 Results
of this study showed that responses were strongly correlated
with the dose administered: 21% of responses with the dose
of 500 mg/m² compared with 75% after the administration of
the higher dose of 2250 mg/m². Toxicity in the dosage range
of 500 mg up to 1500 mg/m² was very uncommon, and maxi-
mum tolerated dose was 2250 mg/m². Infusion-related events
were mostly associated with the first infusion of 375 mg/m².

In another study of dose intensity, Byrd et al increased the
frequency of the standard rituximab dose to 3 times per week.
The same regimen was applied in six untreated patients, and
an ORR of 83% was obtained.58

Even if these studies indicated that increased doses of
rituximab are effective, median time to progression was of
short duration in both studies (8 and 11 months, respectively).
Furthermore these schedules are not applicable in routine
medical practice and, therefore, other strategies to increase
the efficacy of rituximab have been considered.

### Rituximab in combination
with purine analogs

#### Rituximab plus fludarabine

Rituximab enhances the activity of purine analog-based
therapies and has been incorporated into immunochemo-
therapy regimens.59

In vitro studies have demonstrated that apoptosis is
enhanced in an additive or synergistic manner when ritux-
imab is combined with chemo- or immunotherapy molecules.
Cultured CLL and NHL cells treated with 10 µg/mL ritux-
imab lessened the inhibitory concentration needed by various
chemotherapeutic agents to induce apoptosis via increased
p53 and activated caspase-3, -7, and -8, irrespective of the
addition of exogenous complement proteins.65,66 Rituximab,
by downmodulating the expression of the antiapoptotic
protein bcl-2, may sensitize leukemia cells to fludarabine-
duced apoptosis.65 Furthermore, fludarabine downmodu-
lates expression of complement resistance proteins CD46,
CD56, and CD59 on malignant B-cells and renders them
more susceptible to rituximab-induced CDC.45

Fludarabine is one of the most commonly used chemo-
therapeutic agents in CLL, having an independent single-
agent activity and no overlapping toxicity with rituximab.
As the purine analog synergizes in vitro with rituximab, most
studies of immunochemotherapy have focused on regimens of
combinations of rituximab with fludarabine or fludarabine.

The Cancer and Leukemia Group B (CALGB) conducted
a randomized Phase II clinical trial to determine the ideal
administration schedule of rituximab plus fludarabine
in untreated patients (CALGB 9712).67 Patients were
randomized to receive one course every 4 weeks for 6 months of concurrent fludarabine and rituximab followed by four rituximab consolidation courses or sequential treatment of fludarabine alone followed by four infusions of rituximab as consolidation.

The concurrent schedule was shown to be more effective than the sequential in achieving a higher CR rate (47% vs 28%), while the ORR (90% vs 77%) and PFS did not differ significantly between the two groups. Recently updated long-term follow-up of patients enrolled on CALGB 9712 demonstrated extended OS and PFS, with an estimated 17% of responders still in remission after 8 years. The results of this study were retrospectively compared with the outcome of patients treated with fludarabine alone in the CALGB 9011 study. Patients assigned to receive fludarabine and rituximab had a higher incidence of CR and a significantly improved 2-year PFS and OS compared with patients receiving the purine analog alone. It is worth noting that 74% of patients treated with rituximab combined with fludarabine showed a higher incidence of grade 3–4 neutropenia, although no difference in other hematological toxicity or infection development was noted.

The promising results obtained in the CALGB 9712 are in line with those of the Phase II study of the German CLL study group (GCLLSG). Fludarabine at the standard dose of 25 mg/m² for four cycles associated with four infusions of rituximab led to an ORR of 87% with a CR rate of 33%. Similar responses were obtained in both untreated or previously treated patients enrolled in the study. This response rate was achieved after the administration of four courses of treatment and compares favorably with those reported with the most effective chemotherapy combinations in which six courses are generally administered, thus allowing the administration of a lower total dose of fludarabine.

One of the major risks when combining rituximab, which causes a prolonged depletion of B-cell lymphocytes, with fludarabine, which is responsible for profound and prolonged T-cells depletion, is the development of opportunistic infections. Both these studies showed that the frequency of infections was not increased after the immunochemotherapy treatment. Most of the opportunistic infections observed were of viral origin and this warrants an adequate prophylaxis against herpes virus.

Rituximab plus fludarabine and cyclophosphamide

Phase II trials

The combination of fludarabine, cyclophosphamide and rituximab (FCR) was first evaluated at the MD Anderson Cancer Center in previously treated and untreated CLL patients. Fludarabine and cyclophosphamide (FC) were administered at doses of 25 and 250 mg/m², respectively, for 3 days. To prevent the risk of tumor lysis syndrome the first dose of rituximab was 375 mg/m² increasing to 500 mg/m² from the second to the sixth doses.

In the 177 previously treated patients the ORR was 73%, 25% of cases reached a CR and median time to progression of responding patients of 28 months. The results of this study revealed some important issues. Even if the comparability with previously reported Phase II studies is limited, the authors reported higher responses and CR rates and longer PFS with the combination immunochemotherapy compared with those reported for FC alone.

Furthermore previous treatment with FC does not have a detrimental effect on response to FCR, as in this group of patients CR and OR rates obtained were similar to those for the entire group and to those for patients treated with only alkylating agents. Number of responses observed in the fludarabine-refractory group of patients (6% CRs, 58% ORs) was lower, even though the results were comparable with those reached after salvage treatment with alemtuzumab in the same setting of patients.

It should be emphasized that all six intended courses of treatment were administered to less than 50% of patients (46%). Dose reduction occurred in 25 cases, myelosuppression being the primary reason for dose reduction. Grade 3–4 neutropenia occurred in 62% of courses, and major infections were observed in 5% of courses (16% of patients).

An impressively high ORR together with a good quality of responses has been observed after FCR in first-line treatment. Keating et al reported an ORR of 95% with 70% of CRs in 224 untreated patients. Notably, of the 207 patients evaluated at the end of treatment with flow-cytometry studies, 67% had less than 1% CD5 and CD19 co-expressing cells. This study underlined the importance of eradicating MRD, as there was a strong correlation between probability of relapse and responses as well as CD5/CD19 determined by flow-cytometry response.

Compared with the historical group of patients treated with FC, a higher incidence of myelosuppression with a grade 3–4 neutropenia was detected in 52% of courses, and in 38% after chemotherapy, alone even though the incidence of major infections was similar in 2.6% of courses. Time to progression and time to treatment failure survival were significantly better with FCR than with FC.

Recently Tam et al reported the update of the MD Anderson Cancer Center experience on 300 patients receiving FCR. bowlus. 

www.dovepress.com

Dovepress
as initial therapy. The impressive clinical activity was confirmed by a CR rate of 72% and 42% of CR patients reaching PCR negativity. Six-year OS and failure-free survival were 77% and 51%, respectively, and median time to progression was 80 months. MRD negativity, determined by flow-cytometry and PCR, was correlated with superior time to progression (median 85 vs 49 months) and survival (84% vs 65%) at 6 years. Karyotypic abnormalities other than those involving chromosome 17 had no effect on CR or survival. In addition it should be noted that immunochemotherapy with FCR may overcome the adverse prognostic significance of del11q. The extended follow-up of patients permitted the evaluation of late toxicity during remission. Following completion of therapy, 19% of patients had persistent cytopenia lasting more than 3 months. Recurrent late cytopenia episodes occurred, predominantly during the first year, in 28% of 245 patients; the risk of serious or opportunistic infection was 10% and 4% during the first and second years of remission, respectively.

**Phase III trials**

The benefit of adding rituximab to FC has also been examined in prospective randomized trials in previously treated or untreated patients.

The REACH trial was designed to directly compare FCR with FC alone in patients with previously treated CLL. The findings of this multicenter randomized trial including 552 patients supported the results reported in Phase II single-institution studies. In the group of patients randomized to receive the monoclonal antibody, significant improvement of ORR, CR and PFS was observed. Of note, both Binet stage B and C patients benefited from FCR as did patients with poor prognostic features such as del11q, unmutated IgVH and positive ZAP-70. Overall survival was not significantly improved but follow-up was relatively short and a post-trial crossover to rituximab had occurred. As reported in other studies, patients treated with FCR showed a higher rate on grade 3–4 neutropenia even if there was no increase in overall or severe infections.

The superiority of FCR over FC was also confirmed in the 877 untreated patients enrolled in the randomized GCLLSG (CLL8). FCR induced a higher ORR than FC (95 vs 88%), more CRs (44% vs 22%; P < 0.001) and longer median PFS (51.8 months vs 32.8 months). It should be emphasized that this is the first randomized study to demonstrate a superiority in OS (at 37.7 months 84.1% vs 79.0%) between the two treatment arms, even if this superiority was demonstrated only in Binet stages A and B patients.

The importance of eradicating MRD was confirmed by the GCLLSG CLL8 trial, which demonstrated that median PFS depended on the ability to eradicate MRD in the peripheral blood.

Hematological toxicity was higher in the FCR group of patients, even though the mean number of courses delivered in the two groups of patients was similar. 5.2 in the FCR arm versus 4.8 courses in the FC, with a total median cumulative dose of chemotherapy applied per patient. No statistically significant difference between the two treatments was observed.

The results of Phase III trials of rituximab combined with fludarabine alone (FR) or with cyclophosphamide (FCR) are summarized in Table 2.

In a randomized study of untreated patients, FCR was shown to be more effective and to have a better safety profile compared with the same regimen combined with alemtuzumab (FCCam). This study was closed prematurely because of excessive toxicity observed in the FCCam arm.

The efficacy of the FCR combination as well as the possible associated toxicities led to the investigation of two different regimens in which the three drugs were combined at different dosages or were administered sequentially with the aim of reducing dosages or were administered sequentially with the aim of reducing toxicity while preserving efficacy.

Foon et al tested a reduced version of FCR (FCR-Lite) in untreated patients. Fludarabine was dose reduced to 20 mg/m² and cyclophosphamide to 150 mg/m² while rituximab was increased to 500 mg/m² on days 1 and 14 of a 28-day cycle and was also given as consolidation treatment until relapse. All the 48 assessed patients responded to treatment, 38 patients reaching a CR (79%) and 37 showing a negative flow-cytometry. Similar to other studies with FCR, the high-risk feature of del17p was associated with a poor response. None of the patients who entered CR showed disease progression after a median of 22.3 months. Even if the reported follow-up is rather short to enable the outcome to be compared with other FCR studies, this study demonstrated that a high ORR can be reached with a reduced dose of chemotherapy, clearly showing a major reduction in grade 3–4 neutropenia (13% of cycles).

At the Memorial Sloan-Kettering Cancer Center, fludarabine, cyclophosphamide and rituximab were sequentially administered. Initially patients received fludarabine for 6 cycles at the standard dose of 25 mg/m² for 5 days, thereafter cyclophosphamide was given as consolidation treatment for 3 cycles at the dose of 3000 mg/m² every 3 weeks followed by consolidation with rituximab infusions once a week for four weeks. The sequential regimen showed significant efficacy, with an ORR of 89% including 61% of
### Table 2 Phase III trials of rituximab with fludarabine alone or in combination with cyclophosphamide

<table>
<thead>
<tr>
<th>Authors</th>
<th>Comp. study</th>
<th>No. evaluable pts</th>
<th>Disease status</th>
<th>Treatment regimen</th>
<th>Clinical response</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Byrd et al[^7]</td>
<td>Yes</td>
<td>104</td>
<td>Untreated</td>
<td>Sequential: F 25 mg/m² iv × 5 d 6 cycles, after 2 mo R 375 mg/m² iv 4 weekly dose versus Concurrent: F 25 mg/m² iv × 5 d 6 cycles, R 375 mg/m² iv d 1 and 4 cycle 1, d 1 of cycles 2–6 after 2 mo R 375 mg/m² iv 4 weekly doses</td>
<td>47</td>
<td>90</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All enrolled patients:</td>
</tr>
<tr>
<td>Schulz et al[^9]</td>
<td>No</td>
<td>31</td>
<td>20 untreated</td>
<td>Concurrent: F 25 mg/m² iv d 1–5, 29–33, 57–61, 85–89 and R 375 mg/m² iv d 57, 85, 113, 151</td>
<td>28</td>
<td>77</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 y PFS probability 0.67</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 y OS probability 0.93</td>
</tr>
<tr>
<td>Wierda et al[^4]</td>
<td>No</td>
<td>177</td>
<td>Pretreated</td>
<td>FCR: R 375 mg/m² iv first cycle, 500 mg/m² iv d 1 cycles 2–6, F 25 mg/m² iv and CTX 250 mg/m² iv d 2–4 cycle 1, d 1–3 cycles 2–6 every 4 weeks</td>
<td>20</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Median DoR 75 weeks</td>
</tr>
<tr>
<td>Tam et al[^7]</td>
<td>No</td>
<td>300</td>
<td>Untreated</td>
<td>FCR: R 375 mg/m² iv first cycle, 500 mg/m² iv d 1 cycles 2–6, F 25 mg/m² iv and CTX 250 mg/m² iv d 2–4 cycle 1, d 1–3 cycles 2–6 every 4 weeks</td>
<td>72</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Median TTP: 28 mo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Estimated median</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OS: 42 mo</td>
</tr>
<tr>
<td>Robak et al[^8]</td>
<td>Yes</td>
<td>552</td>
<td>Pretreated</td>
<td>FC: F 25 mg/m² iv and CTX 250 mg/m² iv d 1–3 every 4 weeks versus FCR: R 375 mg/m² iv first cycle, 500 mg/m² iv d 1 cycles 2–6, every 4 weeks</td>
<td>13</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Median PFS 20.6 mo,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OS 52 mo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Median PFS 30.6 mo,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OS NR</td>
</tr>
<tr>
<td>Hallek et al[^9]</td>
<td>Yes</td>
<td>817</td>
<td>Untreated</td>
<td>FC: F 25 mg/m² iv and CTX 250 mg/m² iv d 1–3 versus FCR: R 375 mg/m² iv first cycle, 500 mg/m² iv d 1 cycles 2–6, every 4 weeks</td>
<td>22</td>
<td>88</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OS rate at 37.7 mo:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>79%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lepretre et al[^10]</td>
<td>Yes</td>
<td>100</td>
<td>Untreated</td>
<td>FCR: F 40 mg/m² oral d 1–3 and CTX 250 mg/m² oral d 1–3 plus R 375 mg/m² iv d 0 at first cycle and 500 mg/m² d 1 all subsequent cycles versus FCCam: F 40 mg/m² oral d 1–3 and CTX 250 mg/m² oral d 1–3 plus Cam 30 mg sc d 1–3</td>
<td>78</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Not evaluable</td>
</tr>
<tr>
<td>Foon et al[^11]</td>
<td>No</td>
<td>48</td>
<td>Untreated</td>
<td>FCR-Lite: F 20 mg/m² iv d 2–4 first cycle, d 1–3 cycles 2–6, CTX 150 mg/m² iv d 2–4 first cycle, d 1–3 cycles 2–6 R 375 mg/m² iv d 1 cycles 1, 500 mg/m² iv d 14 cycle 1, R 500 mg/m² iv d 1, 14 cycles 2–6; maintenance R 500 mg/m² iv every 3 mo</td>
<td>77</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Median DoR 22.3 mo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None of the CR pts</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>relapsed</td>
</tr>
<tr>
<td>Lamanna et al[^2]</td>
<td>No</td>
<td>36</td>
<td>Untreated</td>
<td>Sequential FCR: F 25 mg/m² iv for 5 d every 4 weeks for 6 cycles, after 4–6 weeks CTX 3000 mg/m² iv every 4 weeks for 3 doses, after 4 weeks 375 mg/m² iv once weekly for 4 doses</td>
<td>61</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Median DoR 43 mo</td>
</tr>
</tbody>
</table>

**Abbreviations:** comp., comparative; pts, patients; CR, complete response; OR, overall response; OS, overall survival; PFS, progression-free survival; DoR, duration of response; TTP, time to progression; F, fludarabine; R, rituximab; CTX, cyclophosphamide; Cam, Campath-1H (alemtuzumab); d, days; mo, months; iv, intravenous; sc, subcutaneous; NR, not reached; FCL-Lite, FCR reduced version.
The majority of the enrolled patients presented a high-risk disease according to stage and prognostic features. The addition of rituximab improved the CR rate and the quality of responses: MRD eradication determined by flow-cytometry or by patient/tumor-specific nucleotide primers PCR was achieved in 56% and 33% of cases, respectively.

Rituximab in combination with other purine analogs

Pentostatin, among purine analogs active in CLL, appears to be less myelosuppressive than fludarabine. The degree of myelosuppression seems to be favorable, even when pentostatin is combined with cyclophosphamide, compared with fludarabine-based combinations. Several studies have investigated the efficacy of the combination pentostatin, cyclophosphamide and rituximab (PCR) either in previously treated or untreated CLL patients (Table 3).

In a cohort of 32 previously treated CLL patients, Lamanna et al reported an ORR of 75%, including 25% of CRs, with a median response duration of 25 months and a median time to treatment failure of 40 months. These authors compared their results with those obtained at the MD Anderson Cancer Center after FCR treatment in the same setting of patients. Even if there are inherent limitations in this comparison, they noted that responses were virtually identical in the two treatment regimens and median survival of all patients was comparable. The frequency of grade 3–4 neutropenia and infectious complications including fever of unknown origin reported after PCR were inferior to those reported after FCR. Moreover, PCR was better tolerated, as a high proportion of patients received all planned therapy at full dose (72% vs 38% with FCR).

The efficacy of PCR, with pentostatin administered at the dose of 2 mg/m², has also been documented in 64 untreated patients. In a subsequent study Shanafelt et al reported that PCR can be safely administered to older patients (≥70 years) and those with modestly decreased creatinine clearance. These results appear to contrast with the tolerability of the FCR regimen: in the PCR study older patients were as likely as younger patients to complete the intended 6 cycles and to achieve CR (41 vs 39%) or PR (52 vs 44%) without excess of grade 3–4 toxicity.

To find out whether results obtained with immunochemotherapy regimens in academic centers are reproducible in the community setting, Reynolds et al carried out a Phase III randomized trial to compare FCR and PCR in previously untreated or minimally treated B-cell CLL. The primary endpoint, incidence of grade 3–4 infections, was similar in the two arms.

Only 50% of patients in both arms completed therapy, resulting in low OR rates that were not statistically different between the two treatment groups. The reason for not completing therapy could be related to the choice of drug dosages. Pentostatin was administered at the higher dosage of 4 mg/m² while in the FCR regimen patients received fludarabine 20 mg/m² for 5 days and cyclophosphamide at 600 mg/m² in 1 day.

To improve tolerability while preserving efficacy, the higher dosage of pentostatin (4 mg/m²) has also been used in association with rituximab, without cyclophosphamide, in first-line treatment. This combination led to lower OR (76%) and CR rates (27%) as well as shorter treatment-free survival compared with the PCR regimen. These results support previous findings on the importance of adding cyclophosphamide to purine analogs and rituximab to improve response rates and prolong PFS.

There is only one published study on the combination of rituximab and intravenous cladribine (RC) with or without cyclophosphamide in refractory and relapsed CLL patients. The objective response observed (78%) was in line with the other immunochemotherapy regimens and superior to cladribine used alone or in combination with cyclophosphamide. The objective response observed (78%) was in line with the other immunochemotherapy regimens and superior to cladribine used alone or in combination with cyclophosphamide. As observed when combining rituximab with fludarabine, the addition of the monoclonal antibody to cladribine did not confer a higher infectious rate. Even though this is a small series of patients, the authors noted that the response ratio was similar in patients treated with or without cyclophosphamide. The efficacy on CLL and SLL of cladribine administered subcutaneously with rituximab has been recently reported. Considering that four courses of therapy were administered and that 38% of patients had been previously treated, an impressive 50% CRs (54% untreated; 44% pretreated) was reported.

Rituximab in combination with other chemotherapeutic agents

The results of the studies are summarized in Table 4.

Rituximab plus bendamustine

Recently the particular mechanism of action of bendamustine, an alkylating agent with additional properties of a purine analog, has reawakened interest in this drug that has been extensively studied in indolent NHL and in CLL. The preclinical observations demonstrating synergistic pro-apoptotic effects of bendamustine and rituximab (BR) supported clinical studies combining the two agents.

The GCLLSG initiated the CLL2M phase II study to investigate the combination of bendamustine at 70 mg/m²
### Table 3 Rituximab in combination treatment with pentostatin or cladribine

<table>
<thead>
<tr>
<th>Authors</th>
<th>Comp. study</th>
<th>No. evaluable pts</th>
<th>Disease status</th>
<th>Regimen</th>
<th>Response</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamanna et al⁸⁴</td>
<td>No</td>
<td>32</td>
<td>Pretreated</td>
<td>PCR: P 4 mg/m² iv d 1, CTX 600 mg/m² iv d 1, R 375 mg/m² iv d 1 omitted from cycle 1</td>
<td>24 (75%) OR, 8 (25%) CR</td>
<td>Median DoR: 25 mo, Median TTF: 40 mo, NR for CR</td>
</tr>
<tr>
<td>Kay et al⁸⁵</td>
<td>No</td>
<td>64</td>
<td>Untreated</td>
<td>PCR: P 2 mg/m² iv d 1, CTX 600 mg/m² iv d 1, R 375 mg/m² iv d 1 every 21 d for 6 cycles</td>
<td>58 (91%) OR, 26 (41%) CR</td>
<td>Median DoR: 34 mo, Median PFS: 32.6 mo</td>
</tr>
<tr>
<td>Shanafelt et al⁸⁶</td>
<td>No</td>
<td>46 &lt; 70 y</td>
<td>Untreated</td>
<td>PCR: P 2 mg/m² iv d 1, CTX 600 mg/m² iv d 1, R 375 mg/m² iv d 1 for 6 cycles</td>
<td>43 (93%) OR, 19 (41%) CR</td>
<td>PFS not different between the 2 age groups</td>
</tr>
<tr>
<td></td>
<td>18 ≥ 70 y</td>
<td></td>
<td></td>
<td></td>
<td>15 (83%) OR, 7 (39%) CR</td>
<td></td>
</tr>
<tr>
<td>Reynolds et al⁸⁷</td>
<td>Yes</td>
<td>184</td>
<td>80% untreated</td>
<td>PCR: P 4 mg/m² iv d 1, CTX 600 mg/m² iv d 1, R 375 mg/m² iv d 1 every 21 days</td>
<td>41 (45%) OR</td>
<td>No differences in survival detected</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20% pretreated</td>
<td>versus FCR: F 20 mg/m² iv d 1–5, CTX 600 mg/m² iv d 1, R 375 mg/m² iv d 1 every 28 days</td>
<td>6 (7%) CR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>53 (57.5%) OR, 15 (17%) CR</td>
<td></td>
</tr>
<tr>
<td>Kay et al⁸⁸</td>
<td>No</td>
<td>33</td>
<td>Untreated</td>
<td>PR: P 4 mg/m² iv d 1, R 100 mg iv d 1, 375 mg/m² iv d 3 and d 5 for cycle 1, 375 mg/m² iv d 1 cycles 2-6; cycles were administered every 21 days</td>
<td>25 (76%) OR, 9 (27%) CR</td>
<td>Median DoR: 10.8 mo, Median TFS: 15.8 mo, Median TTR: 13.6 mo</td>
</tr>
<tr>
<td>Robak et al⁹⁰</td>
<td>No</td>
<td>18</td>
<td>Pretreated</td>
<td>RC: R 375 mg/m² iv d 1, 2-CdA 0.12 mg/kg/d iv d 2-6 every 28 days</td>
<td>12 (67%) OR, 1 (6%) CR</td>
<td>Median PFS: 12 mo</td>
</tr>
<tr>
<td>Bertazzoni et al⁹¹</td>
<td>No</td>
<td>42</td>
<td>62% untreated</td>
<td>R 375 mg/m² iv d 1, 2-CdA 0.1 mg/kg/d sc d 2-6 every 28 days</td>
<td>37 (88%) OR, 21 (50%) CR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>28 CLL/14 SLL</td>
<td></td>
<td>38% pretreated</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** comp., comparative; P, pentostatin; R, rituximab; CTX, cyclophosphamide; 2-CdA, cladribine; pts, patients; d, days; OR, overall response; CR, complete response; DoR, duration of response; TTF, time to treatment failure; PFS, progression-free survival; TTR, time to retreatment; TFS, time-free survival; NR, not reached; mo, months; SLL, small lymphocytic lymphoma; iv, intravenous; sc, subcutaneous.
Table 4 Chemotherapeutic regimens including rituximab

<table>
<thead>
<tr>
<th>References</th>
<th>Comp. study</th>
<th>No. evaluable pts</th>
<th>Prior therapy</th>
<th>Treatment regimen</th>
<th>Clinical response</th>
<th>Survival/duration of response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fischer et al(^a)</td>
<td>No</td>
<td>62</td>
<td>Pretreated</td>
<td>BR: B 70 mg/m(^2) iv d 1–2, R 500 mg/m(^2) iv d 1 (375 mg/m(^2) iv first cycle)</td>
<td>15</td>
<td>Not evaluable</td>
</tr>
<tr>
<td>Fischer et al(^b)</td>
<td>No</td>
<td>117</td>
<td>Untreated</td>
<td>BR: B 90 mg/m(^2) iv d 1–2, R 500 mg/m(^2) iv d 1 (375 mg/m(^2) iv first course), every 4 weeks for up to 6 cycles every 4 weeks</td>
<td>33</td>
<td>Median PFS not reached after 18 mo of follow-up</td>
</tr>
<tr>
<td>Weide et al(^d)</td>
<td>No</td>
<td>39</td>
<td>Pretreated</td>
<td>BMR: B 90 mg/m(^2) iv d 2, 8 every 4 weeks</td>
<td>10</td>
<td>Median TTR: 13 mo</td>
</tr>
<tr>
<td>Hillmen et al(^d)</td>
<td>No</td>
<td>47</td>
<td>Untreated</td>
<td>R 375 mg/m(^2) iv d 1 cycle 1, 500 mg/m(^2) iv cycles 2–6, Chl d 1–7 10 mg/m(^2)/d oral every 28 days for 6 cycles; a further 6 cycles of Chl alone permitted in pts with continuing clinical response at 6 cycles</td>
<td>–</td>
<td>Not evaluable</td>
</tr>
<tr>
<td>Hillmen et al(^d)</td>
<td>Yes</td>
<td>46</td>
<td>Pretreated</td>
<td>FCM: F 24 mg/m(^2) oral d 1–5, CTX 150 mg/m(^2) oral d 1–5, MIT 6 mg/m(^2) iv d 1 for up to 6 courses</td>
<td>16</td>
<td>Not evaluable</td>
</tr>
<tr>
<td>Bosch et al(^d)</td>
<td>No</td>
<td>72</td>
<td>Untreated</td>
<td>FCM-R: F 25 mg/m(^2) iv d 1–4, CTX 250 mg/m(^2) d 1–4, MIT 6 mg/m(^2) iv d 1, R 375–500 mg/m(^2) iv d 1 every 4 weeks</td>
<td>82</td>
<td>Not evaluable</td>
</tr>
<tr>
<td>Faderl et al(^d)</td>
<td>No</td>
<td>30</td>
<td>Untreated</td>
<td>FCM-R: F 25 mg/m(^2) iv d 2–4 cycle 1, d 1–3 cycles 2–6, CTX 250 mg/m(^2) iv d 2–4 cycle 1, d 1–3 cycles 2–6, MIT 6 mg/m(^2) iv d 2 cycle 1, d 1 cycles 2–6, R 500 mg/m(^2) iv d 1 (375 mg/m(^2) iv first cycle) every 4 weeks</td>
<td>83</td>
<td>After a median follow-up of 38.5 mo: TTF NR</td>
</tr>
<tr>
<td>Tsimberidou et al(^d)</td>
<td>No</td>
<td>30</td>
<td>Pretreated</td>
<td>OFAR (oxaliplatin dose finding): O 17.5, 20, or 25 mg/m(^2) iv d 1–4, F 30 mg/m(^2) iv d 2–3, cytarabine 1 g/m(^2) iv d 2–3, R 375 mg/m(^2) iv d 1 or d 3 every 4 weeks for up to 6 cycles</td>
<td>7</td>
<td>Median DoR 10 mo At 6 mo: FFS 48% and OS 89%</td>
</tr>
<tr>
<td>Tsimberidou et al(^d)</td>
<td>No</td>
<td>67</td>
<td>Pretreated</td>
<td>OFAR 2: O 30 mg/m(^2) iv d 1–4, R 375 mg/m(^2) iv d 3, and pelgrstim 6 mg d 6, F 30 mg/m(^2) iv and cytarabine 500 mg/m(^2) iv d 2–3 (dose level 1) d 2–4 (dose level 2) or d 2–5 (dose level 3) every 4 weeks</td>
<td>4</td>
<td>Median survival duration 21 mo</td>
</tr>
</tbody>
</table>

Abbreviations: comp., comparative; B, bendamustine; R, rituximab; CTX, cyclophosphamide; F, fludarabine; O, oxaliplatin; MIT, mitoxantrone; Chl, chlorambucil; pts, patients; d, days; OR, overall response; CR, complete response; DoR, duration of response; TTF, time to treatment failure; PFS, progression-free survival; NR, not reached; mo, months; iv, intravenous; sc, subcutaneous.
on two consecutive days plus rituximab on day 1 at a dose of 375 mg/m² for the first course and 500 mg/m² during subsequent cycles in 81 relapsed CLL patients.\cite{92} BR treatment was administered every 28 days for up to six courses. In the 62 patients assessable for response, the ORR was 77.4% with a CR rate of 14.5% of patients. Of note is that a high ORR (92%) was observed among patients with del11q. Major but tolerable treatment toxicities were myelosuppression and infections. Grade 3–4 infections were documented in 5% of all given cycles.

Based on these interesting results BR was considered in first-line treatment in a multicenter Phase II study of the GCLLSG.\cite{93} Preliminary results on 117 CLL patients showed an ORR of 90.9% with a CR in 32.7% of cases. After 18 months 75.8% of the patients were still in remission with a median PFS not reached. Grade 3–4 infections occurred in 5% of all administered courses. As in the previously treated patients, BR confirmed its efficacy even among patients with adverse prognostic features such as del11q and unmutated IgVH status, leading to ORR of 90.5% and 88.9%, respectively. Patients with del17p achieved only PRs (42.9%). The GCLLSG is presently investigating the efficacy of BR in comparison with fludarabine-based immunochemotherapy (FCM) as first-line treatment of CLL within a randomized Phase III trial (CLL10 protocol).

In a recently published retrospective trial, Weide et al evaluated 39 elderly patients with relapsed or refractory CLL who were treated with bendamustine, mitoxantrone and rituximab (BMR).\cite{94} Treatment consisted of bendamustine 90 mg/m² on days 1 to 2, mitoxantrone 6 mg/m² on day 1 and rituximab 375 mg/m² on days 8, 15, 22 and 29. ORR was 92% (10% CR, 82% PR), with many patients receiving only a single cycle of immunochemotherapy. Median time to next CLL therapy was 13 months (0–69). Therapy was well tolerated, with two observed therapy-associated hospitalizations. A reversible grade 3–4 hematological toxicity was seen in 30 patients (77%).

**Rituximab plus chlorambucil**

Despite the increasing use of fludarabine-containing regimens and more recently FCM, chlorambucil remains a first-line treatment option, particularly for elderly patients and those with co-morbidities.\cite{95} However, rates of CR obtained with the alkylating agents are relatively low (up to 7%) as are overall responses (approximately 65%). In the United Kingdom (UK) a phase II study is ongoing designed with the aim of assessing the feasibility of adding rituximab to chlorambucil in order to improve outcomes.\cite{96} Treatment consisted of rituximab (375 mg/m² day 1 in the first cycle, 500 mg/m² in cycles 2–6) plus chlorambucil (10 mg/m² days 1–7) repeated every 28 days for six cycles. A further six cycles of chlorambucil alone was permitted in patients with continuing clinical response at six cycles. The interim analysis on 50 patients showed an ORR of 84%, which is 17.3% higher than in the well-matched subset of patients from the UK LRF CLL4 study treated with chlorambucil in monotherapy.\cite{97} The high median age of patients entered in the study and the good tolerance, even in older patients, suggest that this combination treatment may be considered in those patients who cannot tolerate a more intensive regimen.

**Rituximab plus fludarabine, cyclophosphamide, and mitoxantrone**

The combination fludarabine, cyclophosphamide, and mitoxantrone (FCM) has been extensively, used demonstrating a high effectiveness in CLL patients both previously untreated and treated.\cite{98,99,100} The next logical development of this treatment program was to investigate the role of rituximab addition (FCM-R). Hillmen et al reported the results of a small Phase II randomized trial which attempted to compare FCM with FCM-R in pretreated patients. CR rate was higher in patients receiving the monoclonal antibody (43%) even though the small number of patients did not allow statistically valid conclusions. Once again, this trial demonstrated that the addition of the monoclonal antibody did not increase toxicity, as the rate of serious adverse events was similar in the two treatment arms.\cite{101}

Bosch et al treated 72 naïve CLL patients with this combination, obtaining a 93% ORR including 82% CRs, of which 46% were MRD negative, using multiparametric flow-cytometry. Results of the FCM clinical study were retrospectively compared with those of the immunochemotherapeutic regimen. Although the ORR rate was similar with the two treatment programs, the proportions of CRs and MRD negativity were significantly higher in patients receiving rituximab.\cite{102} Variables associated with a lower CR, even with immunochemotherapy, included beta2-microglobulin and del17p. Severe neutropenia and infections were higher in patients treated with FCM-R even when comparing only the group of younger patients (age <65 years).

The same regimen with a higher dosage of rituximab (FCM-R) was investigated by Faderl et al in a pilot study of 30 untreated CLL patients in an attempt not to compare immunochemotherapy with chemotherapy, but to evaluate whether mitoxantrone addition to FCR provided any substantial benefit.\cite{103} The authors concluded that compared to
FCR the addition of mitoxantrone does not seem to give more benefit when looking at clinical flow-cytometry or molecular responses. Further follow-up is required to assess the benefit in terms of time to treatment failure. The frequency of severe neutropenia was similar between FCM-R and FCR and in general the addition of mitoxantrone was associated with a greater myelosuppressive effect, since every patient received hematopoietic growth factor. The small number of patients enrolled in this study does not allow conclusions to be drawn on the influence of mitoxantrone on particular subgroups of patients.

Rituximab plus fludarabine, oxaliplatin, and cytarabine

Rituximab was also combined with fludarabine, oxaliplatin, and cytarabine (OFAR) in a Phase I/II dose-finding study for patients with fludarabine-refractory CLL. After a median number of two courses, ORR achieved in this high-risk group of patients was 33%, with responses observed only in cases treated with the higher oxaliplatin dosage of 25 mg/m². Responses were high, 33%, even in the subset of patients carrying the 17p deletion. The superiority of OFAR compared with other cisplatin-based therapies could be attributed to the substitution of oxaliplatin for cisplatin, the considerable dose of cytarabine administered and the addition of the monoclonal anti-CD20 antibody. A subsequent study (OFAR2) with rituximab in association with the same chemotherapeutic agents, administered at different dose levels (higher oxaliplatin, lower cytarabine dosages), confirmed the high efficacy of the combination in 52 refractory CLL patients. A response was achieved in 63% of patients, with a high antileukemic activity in patients with del17p; median survival duration was 21 months.

Rituximab in combination with monoclonal antibodies

The rationale of combination treatment with monoclonal antibodies is based on: suboptimal efficacy of single-agent monoclonal antibody therapy, different molecular targets of the antibodies and different mechanism of action.

Rituximab and alemtuzumab

Alemtuzumab is a monoclonal humanized antibody specific for the CD52 antigen which is expressed at high levels in CLL cells and is active in initial and salvage therapy. Treatment with alemtuzumab is warranted in patients with del17p and/or p53 mutations, both of which have been associated with resistance to most other available CLL treatment agents.

A pilot study to evaluate efficacy and tolerability of the combination of rituximab and alemtuzumab was performed in 12 heavily pretreated patients failing purine analogs therapy. Patients were treated in three different cohorts: rituximab 375 mg/m² was administered weekly for 4 weeks while alemtuzumab dosage was escalated in the different cohorts according to toxicity (3 mg, 10 mg, 30 mg, respectively, 3 times a week for 4 weeks). Although only one patient achieved an objective response, the combination of the two monoclonal antibodies was shown to be safe as no significant myelosuppression was noted and none of the patients developed an opportunistic infection. Cytomegalovirus (CMV) reactivation was not detected in this trial but it should be emphasized that CMV antigenemia was not routinely performed. In an MD Anderson Cancer Center trial the administration with rituximab of the higher dosage of alemtuzumab, 30 mg iv 3 times a week, led to a higher response rate with at least one episode of infection in 52% of treated patients, although none of the infections was fatal. Because a wide range of diagnoses was included in this series, it is difficult to draw any firm conclusion on whether the combination of rituximab and alemtuzumab has any advantage over single-agent monoclonal antibody therapy. In a more recent study, on only CLL patients, the same authors reported on the efficacy of the combination of the two monoclonal antibodies administered at a higher dosages with a different schedule. ORR (53%) and time to treatment failure were similar to those in the previous study, with a trend toward a higher CR rate (18%). Documented infections occurred in 28% of patients but even in this study no fatal infections or opportunistic infections were recorded.

The interest in this combination of two monoclonal antibodies led to its efficacy being investigated as front-line treatment. Frankfurter et al reported the results of subcutaneous alemtuzumab administration in 20 previously untreated and symptomatic patients. A high CR rate was achieved (40%), including all patients with del11q abnormality. Furthermore at the completion of therapy 70% of patients had no evidence of MRD by flow-cytometry.

Zent et al used the combination in untreated asymptomatic patients who had at least one marker of high-risk disease: del17p, del11q or combination of unmutated IgVH and CD38+/ZAP-70+. In both these first-line treatment studies, patients with CMV reactivation were described (30% and 10%, respectively). A low incidence of infections was reported: one patient in the first study developed CMV disease with full recovery after foscarnet, one patient in the second study was hospitalized after neutropenic fever.
Although the combination of the two monoclonal antibodies was demonstrated to be effective, with a low rate of severe infections, the profound immunosuppression documented warrants further investigation in particular subsets of patients, providing careful monitoring of complications.

One possible way to further increase the efficacy observed with FCR might be the addition of the combination of another monoclonal antibody targeting a different antigen.

At the MD Anderson Cancer Center, alemtuzumab 30 mg iv on days 1, 3, and 5 was added to FCR (CFAR regimen) in a first Phase II study with 79 refractory patients. An ORR of 65% and a CR rate of 24% were observed, patients who obtained CR showed a negative by flow-cytometry MRD. As for most salvage treatments CFAR was more active in patients who were sensitive to their previous fludarabine regimen (ORR 74%, CR 36%) than in fludarabine-refractory patients (ORR 49%, CR 6%). It should be emphasized that the regimen was shown to be effective in 44% of patients presenting with 17p deletion. The incidences of major infections (11%), minor infections (28%) and fever of unknown origin (36%) were similar to those observed with FCR in the relapsed setting.

Given these promising results, this combination was subsequently administered as first-line treatment in patients with high-risk features determined as either 17p deletion and/or a high level of beta2-microglobulin (twice the upper normal level). ORR achieved in the whole population was 92%, with 70% of CRs. A CR of 57% was observed in patients with del17p, with an ORR of 78%. Results and toxicities were compared

The addition of alemtuzumab conferred a higher CR rate and bone marrow MRD negativity in the same group of high-risk patients who received FCR only. After the CFAR regimen a higher rate of myelosuppression and CMV reactivation were observed. Incidence of other infections was similar. Treatment discontinuation was observed more often in patients receiving CFAR. The short follow-up of 24 months did not reveal differences in time to progression and OS between CFAR and the historical FCR control group. Longer follow-up will help to determine the role of CFAR in high-risk patients, although the response rate observed in these patients is the highest reported to date.

Rituximab and lumiliximab
Lumiliximab, a monoclonal antibody that binds specifically to CD23, has been tested in association with FCR in 31 refractory/relapsed patients. Although the OR the results observed in this study are very similar to the others reported with FCR alone, the addition of lumiliximab increased CR twofold (65%). Importantly, the addition of the second monoclonal antibody did not increase toxicity. A large global randomized study comparing FCR with FCR plus lumiliximab in previously treated patients is ongoing.

Rituximab in combination with nonchemotherapeutic agents

Rituximab plus steroids
High-dose methylprednisolone (HDMP) is an established treatment in refractory CLL and can induce responses both in bulky disease and p53 mutation. In preclinical studies rituximab was shown to act synergistically with methylprednisolone to induce apoptosis of CLL cells, particularly in the presence of nurse-like cells.

Castro et al were the first to describe the combination of HDMP 1 g/m² for 5 days with rituximab in refractory patients, reporting excellent response rates (93%) and tolerability. Similar results, summarized in Table 5, were observed in the Mayo Clinic retrospective study and in smaller series of heavily pretreated patients (ORR 93% to 75%, median PFS or duration of response 7 to 14 months). In all series a high activity of the combination was reported in patients with aggressive disease features including those with del17p and/or bulky adenopathy, although in all studies a significantly high rate of infection (21.4% to 29%) was observed.

Castro et al conducted a study to evaluate dosing and toxicity of the HDMP and rituximab combination in chemotherapy-naïve patients. Patients received HDMP 1 g/m² for 3 days; rituximab was administered in the first group at the dosage of 375 mg/m² for 12 doses and in the second group at a higher dosage of 750 mg/m² for 9 doses. ORR was 96% with 32% of CRs, 8% of which were MRD negative. It has to be emphasized that all patients >70 years responded to treatment and all cases with del11q and del17p achieved an objective response. No statistical difference in response was observed when patients were categorized according to the rituximab dosage. Median PFS and treatment-free survival were 30.5 and 33.3 months, respectively, and for CR patients median PFS was 40.3 months.

Rituximab and granulocyte-macrophage colony-stimulating factor
Although the synergistic effect of rituximab with chemotherapeutic agents is well known the toxicity of immunochemotherapeutic regimens remains a limitation. The availability of agents that may enhance rituximab’s efficacy without the
myelosuppressive effects of chemotherapy has led to the investigation of cytokine partners.

As the lower density of CD20 antigen in CLL is considered one of the most important factors responsible for reduced rituximab activity, one approach to enhance responses could be the use of cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-4, to upregulate CD20.121

The rationale for using GM-CSF in combination with rituximab is based on the observation of Venugopal et al that CLL patients exposed in vitro to GM-CSF have increased expression of surface CD20, potentially making them a better target for rituximab.121 Furthermore the addition of GM-CSF in vitro enhances rituximab-induced ADCC against CLL cells, stimulating granulocyte and macrophage natural cytotoxicity.122

A phase II study conducted at the MD Anderson Cancer Center demonstrated the efficacy of the combination of rituximab at the standard dose of 375 mg/m² weekly for 4 weeks combined with GM-CSF 250 μg subcutaneously 3 times a week for 8 weeks.123 The ORR observed in the 118 patients treated was 65% with 9% of CRs, 10% of nodular PRs and 53% PRs. The results suggested an improvement in response rate with the combination treatment over rituximab in monotherapy either in untreated or recurrent disease patients. The most common toxicity observed was mild erythema at the site of GM-CSF injection; six episodes of major infections were documented.

Considering the favorable results obtained with GM-CSF plus rituximab and considering the severe myelosuppressive effects observed after immunochemotherapy regimens, GM-CSF could play a role as a myeloid growth factor and in addition synergize with rituximab.

Ferrajoli et al recently reported the preliminary data of GM-CSF given in combination with FCR regimen in front-line treatment.124 The study confirmed the achievement of a high ORR (100%) and CR (72%) rates. Of note, 85% of patients treated with this combination completed all 6 planned courses and only two patients (4%) received fewer than four courses.

**Rituximab plus lenalidomide**

Lenalidomide is an immunomodulatory drug that is a more potent analog of thalidomide. In patients with relapsed/refractory CLL, treatment with single-agent lenalidomide induced an ORR of 32% to 47% when used as monotherapy.125,126 The combination of rituximab and lenalidomide was investigated at the MD Anderson Cancer Center based on the possible enhanced activity of rituximab induced by lenalidomide which stimulates natural killer (NK) cell proliferation.127

Patients were treated with rituximab (375 mg/m²) iv on days 1, 8, 15 and 22 of cycle 1, and then once every 4

### Table 5: Rituximab in combination with high-dose steroids

<table>
<thead>
<tr>
<th>Authors</th>
<th>No. evaluable pts</th>
<th>Disease status</th>
<th>Regimen</th>
<th>Response</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Castro et al</td>
<td>14</td>
<td>Pretreated</td>
<td>HDMP 1 g/m²/d iv for 5 days plus rituximab 375 mg/m² iv d 1, 8, 15, 22 every 4 weeks</td>
<td>13 (93%) OR</td>
<td>Median TTP 15 m</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 (36%) CR</td>
<td>Median TFS 22 m</td>
</tr>
<tr>
<td>Quinn et al</td>
<td>12</td>
<td>Pretreated</td>
<td>Rituximab (dose not stated) plus HDMP 1 g/m²/d iv for 5 days or HDD 40 mg/d iv for 4 days every 4 weeks</td>
<td>9 (75%) OR</td>
<td>Median</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 (8%) CR</td>
<td>DoR: 14 m</td>
</tr>
<tr>
<td>Bowen et al</td>
<td>37</td>
<td>Pretreated</td>
<td>HDMP 1 g/m²/d iv for 5 days plus rituximab 375 mg/m² iv d 1, 8, 15, 22 every 4 weeks</td>
<td>29 (78%) OR</td>
<td>Median PFS: 1 y</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8 (22%) CR</td>
<td>3 y survival: 41.3%</td>
</tr>
<tr>
<td>Dungarwalla et al</td>
<td>14</td>
<td>Pretreated</td>
<td>HDMP 1 g/m²/d iv for 5 days plus rituximab 375 mg/m² iv d 1 every 28 days</td>
<td>13 (93%) OR</td>
<td>Median PFS: 7 m</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (14%) CR</td>
<td>Median OS: 20 m</td>
</tr>
<tr>
<td>Castro et al</td>
<td>28</td>
<td>Untreated</td>
<td>HDMP 1 g/m² iv d 1–3 for 3 courses plus Group 1: rituximab 375 mg/m² iv 12 doses Group 2: rituximab 750 mg/m² iv 9 doses</td>
<td>27 (96%) OR</td>
<td>Median FU 3 y: OS 96%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9 (32%) CR</td>
<td>Median PFS 30.5 m</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Median PFS 33.3 m</td>
</tr>
</tbody>
</table>

**Abbreviations:** pts, patients; HDMP, high-dose methylprednisolone; HDD, high-dose dexamethasone; iv, intravenous; d, days; y, year; OR, overall response; CR, complete response; TTP, time to progression; PFS, progression-free survival; TFS, treatment-free survival; DoR, duration of response; FU, follow-up.
weeks during cycles 3 to 12. Lenalidomide was given orally at the dose of 10 mg/day starting on day 9 of cycle 1 and continued daily for 12 cycles. Recently the results on 37 refractory relapsed patients treated with at least six courses have been reported.128 The ORR (68%) was superior to that with single-agent lenalidomide despite all patients having received prior rituximab. Furthermore no differences in responses among the different prognostic groups were observed. Interestingly, the percentage of CD19+CD20+ B-cells decreased, and the percentages of CD4+ T, CD8+ T, CD4+CD25hiCD127– regulatory T and CD3+CD16+CD56+ NK cells significantly increased.

Rituximab in maintenance therapy

Rituximab is an attractive candidate for maintenance therapy due to a favorable combined efficacy and safety profile, thus allowing extended therapy to improve outcome without compromising quality of life. In low-grade NHL, rituximab maintenance treatment clearly suggests an improvement in outcome following responses obtained with initial rituximab monotherapy or either chemotherapy or immunochemotherapy.129–131

Hainsworth et al administered consolidation treatment with rituximab in four weekly courses, at 6-month intervals, for 2 years in those CLL patients responding or showing a stable disease after initial front-line rituximab monotherapy.59 Consolidation treatment increased ORR from 51% to 58%, and CR rate from 4% to 9%. The median PFS at the time of reporting was 18.6 months with a projected 1-year and 2-year PFS of 62% and 49%, respectively. Long-term toxicity during rituximab maintenance therapy was reported to be mild.

In a similar study rituximab consolidation was evaluated in 28 patients in CR or PR with positive flow-cytometric MRD after fludarabine treatment.132 Rituximab was initially administered for four weekly doses, then MRD-positive patients received 4 monthly cycles of rituximab at 375 mg/m² followed by 12 monthly doses at 150 mg/m². Postinduction therapy significantly increased response duration compared with controls (87% vs 32% at 5 years). Updated results of this study, recently reported, confirmed the long PFS of consolidated patients from the end of induction treatment (40% at 9 years).133

A response-adjusted and flexible low-dose rituximab maintenance regimen was designed for relapsed CLL patients who achieved a partial or minimal response to prior therapy with rituximab.134 Patients received the monoclonal antibody at the dosage of 100 mg on a 4-week schedule, if disease progression occurred during the interval between treatments was reduced or 500 mg of rituximab was given every 2 to 4 weeks. Maintenance therapy was successfully carried out in ≥6 months in 7 of the 12 enrolled patients with mild long-term toxicity. In three cases partial remission or minor response was maintained for relatively long periods (up to 42 months).

Conclusion

In the past 20 years considerable progress had been made in molecular and cellular biology, and prognosis and treatment of patients with CLL. These achievements have provided the basis for the development of innovative and more effective therapies in this disease. Two reports135,136 recently published demonstrated, by comparing cohorts of patients from the 1980s and the 2000s, that survival in CLL patients had significantly improved. These data suggest that improved therapies, particularly in younger patients, might improve OS.

The introduction of rituximab has revolutionized the treatment of lymphoproliferative disorders. In CLL rituximab monotherapy has limited activity in refractory/relapsed patients, with responses being generally inferior to those seen in NHL. Although increasing dose intensity and frequency leads to higher response rates, even in first-line treatment, responses are almost always partial and of short duration. Furthermore the high dosages used are not feasible in routine clinical practice.

On the basis of preclinical evidence of the synergism between rituximab and fludarabine, rituximab has been incorporated into fludarabine-based regimens. Concurrent fludarabine and rituximab has been shown to increase ORR, CR and PFS but not long-term survival benefit. A further amelioration of the quality of responses has been achieved with the FCR. The improvement in PFS resulted directly from an improved ability to eradicate MRD, highlighting the importance of MRD eradication. The CLL8 German randomized trial is the first study demonstrating the superiority of the FCR arm over the comparator (FC) arm in prolonging OS. Based on the demonstrated benefit of FCR treatment, the US Food and Drug Administration has recently approved the new indication of this anti-CD20 monoclonal antibody as treatment of naïve or relapsed CLL, in combination with standard cytotoxic chemotherapy consisting of fludarabine and cyclophosphamide. Despite the demonstrated efficacy of FCR, important issues must still be addressed. Should FCR be considered the ‘standard’ care for all patients?
Selection of the most appropriate initial therapy in CLL must be based primarily on patient characteristics such as age, performance status, co-morbidities and biological disease characteristics. Although the addition of rituximab to FC improved outcome in patients with p53 mutation or del17p, results with this combination treatment are still unsatisfactory so that alternative treatments such as alemtuzumab or investigational therapies should be considered. As of now, FCR should be considered the standard care in young, fit patients in which the reasonable goal of treatment is CR, possibly MRD-negative CR. Although FCR toxicity is manageable and infections are similar to those observed after chemotherapy alone, the high rate of profound myelosuppression, persisting in some cases after the end of therapy, warrants adequate monitoring prophylaxis and high standard of care.

Management decisions can be different in elderly patients with comorbidities, as FCR may be poorly tolerated. This group of patients may benefit from other combination regimens including rituximab (eg, PCR, BR), or alternatively first-line alemtuzumab treatment if severe CLL-related pancytopenia is present.

A large randomized multicenter study showed that results obtained after FCR treatment in clinical trials are not reproducible in the community setting where the majority of patients are treated. Furthermore what has not been answered in a randomized fashion is whether FCR is superior, with a similar tolerability, to other combination regimens such as PCR, FCR-Lite, BR, and R-FCM.

Even if high CR rates with eradication of MRD have been obtained with FCR, a proportion of patients still show a poor outcome. To overcome resistance in the high-risk group of patients new treatment strategies are under investigation. Preliminary results have shown that the FCR regimen with the addition of alemtuzumab is effective in treating high-risk patients in first-line treatment. Opportunistic infections related to concomitant depletion of T- and B-cell lymphocytes when alemtuzumab and rituximab are administered should be strictly monitored. Longer follow-up of the study is needed in order to assess if an advantage in PFS and/or OS is recorded in poor-risk CLL.

Different strategies with nonchemotherapeutic agents are under investigation. The combination of rituximab and lenalidomide has been shown to be more effective than lenalidomide alone in relapsed/refractory patients, even in cases showing adverse prognostic features and bulky disease.

Additional studies based on biological stratification with an adequate follow-up are warranted in order to assess the impact of rituximab combined with new compounds.

Disclosure

The authors report no conflicts of interest.

References

OncoTargets and Therapy 2010:3


31. Hallek M, Fingerle-Rowson G, Finck AM, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial trial on behalf of an international group of investigators and the German CLL Study Group. Blood. 2009;114:Abstract 335.


79. Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). *Blood*. 2008;112:Abstract 325.

80. Lepretre S, Aurran T, Mahe B, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and mabcampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCCLL/MW) and the “Groupe Ouest-Est d’Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS): CLL2007FMP (for fit medically patients). *Blood*. 2009;114:Abstract 538.


